BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost 2020;18:2486-95. [PMID: 32914582 DOI: 10.1111/jth.15006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost 2020;18:2496-502. [PMID: 32914526 DOI: 10.1111/jth.15010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 13.5] [Reference Citation Analysis]
2 Picod A, Veyradier A, Coppo P. Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab? J Thromb Haemost 2021;19:58-67. [PMID: 33236389 DOI: 10.1111/jth.15194] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
3 Tiscia G, Sartori MT, Giuffrida G, Ostuni A, Cascavilla N, Nicolosi D, Battista C, Santeramo TM, Melillo L, Giordano G, Cappucci F, Fischetti L, Chinni E, Tarantini G, Cerbo A, Bertomoro A, Fabris F, Grandone E. Focus on Key Issues in Immune Thrombotic Thrombocytopenic Purpura: Italian Experience of Six Centers. J Clin Med 2021;10:5702. [PMID: 34884404 DOI: 10.3390/jcm10235702] [Reference Citation Analysis]
4 Mancini I, Agosti P, Boscarino M, Ferrari B, Artoni A, Palla R, Spreafico M, Crovetti G, Volpato E, Rossini S, Novelli C, Gattillo S, Barcella L, Salmoiraghi M, Falanga A, Peyvandi F; Lombardy AREU TMA Network. Lombardy diagnostic and therapeutic network of thrombotic microangiopathy. Orphanet J Rare Dis 2022;17:246. [PMID: 35739601 DOI: 10.1186/s13023-022-02400-y] [Reference Citation Analysis]
5 George A, Deepika C, Mohan G, Rajendran V, Shastry S, Blarakrishnan JM, Rao S. ADAMTS13 factor deficiency in severe COVID-19 may not be immune mediated-report from a pilot study. Clin Hemorheol Microcirc 2022. [PMID: 35754264 DOI: 10.3233/CH-221514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Akpinar S, Tekgunduz E, Esen R, Yilmaz M, Karakus V, Vural F, Gediz F, Aydogdu I, Kaynar L, Goker H, Kelkitli E, Ayyildiz O, Demirkan F. Prospective registry of adult patients receiving therapeutic plasma exchange with a presumptive diagnosis of thrombotic microangiopathy (TMA): The Turkish hematology research and education group (ThREG)-TMA02 study. Transfusion and Apheresis Science 2022. [DOI: 10.1016/j.transci.2022.103365] [Reference Citation Analysis]
7 Long B, Bridwell RE, Manchanda S, Gottlieb M. Evaluation and Management of Thrombotic Thrombocytopenic Purpura in the Emergency Department. J Emerg Med 2021;61:674-82. [PMID: 34518045 DOI: 10.1016/j.jemermed.2021.07.045] [Reference Citation Analysis]
8 Favaloro EJ, Pasalic L, Henry B, Lippi G. Laboratory testing for ADAMTS13: Utility for TTP diagnosis/exclusion and beyond. Am J Hematol 2021;96:1049-55. [PMID: 33991361 DOI: 10.1002/ajh.26241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Favaloro EJ, Mohammed S, Chapman K, Swanepoel P, Zebeljan D, Sefhore O, Malan E, Clifford J, Yuen A, Donikian D, Kondo M, Duncan E, Abraham S, Beggs J, Chatrapati R, Perel J, Coleman R, Klose N, Hsu D, Motum P, Tan CW, Brighton T, Pasalic L. A multicenter laboratory assessment of a new automated chemiluminescent assay for ADAMTS13 activity. J Thromb Haemost 2021;19:417-28. [PMID: 33124748 DOI: 10.1111/jth.15157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
10 Akpınar S, Tekgunduz E, Erkurt MA, Esen R, Yılmaz M, Karakus V, Vural F, Gediz F, Aydogdu I, Kaynar L, Korkmaz S, Goker H, Kelkitli E, Ayyıldız O, Demirkan F. Prospective registry of adult patients receiving therapeutic plasma exchange with a presumptive diagnosis of thrombotic microangiopathy (TMA): The Turkish hematology research and education group (ThREG)-TMA02 study. Transfus Apher Sci 2021;:103312. [PMID: 34799244 DOI: 10.1016/j.transci.2021.103312] [Reference Citation Analysis]
11 Chan M, Zhao X, Zheng XL. Low ADAMTS-13 predicts adverse outcomes in hospitalized patients with suspected heparin-induced thrombocytopenia. Res Pract Thromb Haemost 2021;5:e12581. [PMID: 34553121 DOI: 10.1002/rth2.12581] [Reference Citation Analysis]
12 Sui J, Lu R, Halkidis K, Kocher NK, Cao W, Marques MB, Zheng XL. Plasma levels of S100A8/A9, histone/DNA complexes, and cell-free DNA predict adverse outcomes of immune thrombotic thrombocytopenic purpura. J Thromb Haemost 2021;19:370-9. [PMID: 33188723 DOI: 10.1111/jth.15176] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Karsenty CL, Kirk SE, Helber HL, Esquilin JM, Despotovic JM, Grimes AB. Molecular Diagnosis Is Vital to the Accurate Classification and Management of Thrombotic Thrombocytopenic Purpura in Children. Front Immunol 2022;13:836960. [DOI: 10.3389/fimmu.2022.836960] [Reference Citation Analysis]
14 Poullin P. [Treatment of immune-mediated thrombotic thrombocytopenic purpura: A decisive turning point]. Transfus Clin Biol 2021;28:380-5. [PMID: 34464709 DOI: 10.1016/j.tracli.2021.08.347] [Reference Citation Analysis]
15 Lu R, Sui J, Zheng XL. Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura. Blood Adv 2020;4:5378-88. [PMID: 33141886 DOI: 10.1182/bloodadvances.2020003065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;:JCO2101440. [PMID: 34724392 DOI: 10.1200/JCO.21.01440] [Reference Citation Analysis]
17 Jain N, Oldenburg J, Ozelo MC, Sun SX, Tang L, Tzivelekis S. Recent advances in therapeutic options for rare hemostatic disorders: selected poster extracts of recent research in hemophilia A, congenital hemophilia with inhibitors, von Willebrand disease, and thrombotic thrombocytopenic purpura presented at the 29th congress of the International Society on Thrombosis and Haemostasis (ISTH 2021, Jul 17-21; virtual congress). Expert Rev Hematol 2022;:1-18. [PMID: 35748691 DOI: 10.1080/17474086.2022.2074395] [Reference Citation Analysis]
18 Graça NAG, Joly BS, Voorberg J, Vanhoorelbeke K, Béranger N, Veyradier A, Coppo P. TTP: From empiricism for an enigmatic disease to targeted molecular therapies. Br J Haematol 2022. [PMID: 35146746 DOI: 10.1111/bjh.18040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Lämmle B, Rossmann H. Invited commentary to: ADAMTS13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19 by Tiffany Pascreau et al. Letter to the Editors-in-Chief, Thrombosis Research. Thromb Res 2021;204:141-2. [PMID: 33678420 DOI: 10.1016/j.thromres.2021.02.030] [Reference Citation Analysis]
20 Smock KJ. ADAMTS13 testing update: Focus on laboratory aspects of difficult thrombotic thrombocytopenic purpura diagnoses and effects of new therapies. Int J Lab Hematol 2021;43 Suppl 1:103-8. [PMID: 34288437 DOI: 10.1111/ijlh.13557] [Reference Citation Analysis]
21 Zini G, d'Onofrio G, Erber WN, Lee SH, Nagai Y, Basak GW, Lesesve JF; International Council for Standardization in Hematology (ICSH). 2021 update of the 2012 ICSH Recommendations for identification, diagnostic value, and quantitation of schistocytes: Impact and revisions. Int J Lab Hematol 2021;43:1264-71. [PMID: 34431220 DOI: 10.1111/ijlh.13682] [Reference Citation Analysis]
22 Páramo JA. [Microvascular thrombosis and clinical implications]. Med Clin (Barc) 2021;156:609-14. [PMID: 33875227 DOI: 10.1016/j.medcli.2020.12.042] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Memon R, Sui J, Lin C, Zheng XL. Cerebral Infarction in Immune Thrombotic Thrombocytopenic Purpura Is Associated with Old Age, Hypertension, Smoking, and Anti-ADAMTS13 Ig, But Not with Mortality. TH Open 2021;5:e1-7. [PMID: 33458563 DOI: 10.1055/s-0040-1722610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Cuker A, Cataland SR, Coppo P, de la Rubia J, Friedman KD, George JN, Knoebl PN, Kremer Hovinga JA, Lämmle B, Matsumoto M, Pavenski K, Peyvandi F, Sakai K, Sarode R, Thomas MR, Tomiyama Y, Veyradier A, Westwood JP, Scully M. Redefining outcomes in immune TTP: an international working group consensus report. Blood 2021;137:1855-61. [PMID: 33529333 DOI: 10.1182/blood.2020009150] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
25 Nishikawa M, Kanno H, Zhou Y, Xiao TH, Suzuki T, Ibayashi Y, Harmon J, Takizawa S, Hiramatsu K, Nitta N, Kameyama R, Peterson W, Takiguchi J, Shifat-E-Rabbi M, Zhuang Y, Yin X, Rubaiyat AHM, Deng Y, Zhang H, Miyata S, Rohde GK, Iwasaki W, Yatomi Y, Goda K. Massive image-based single-cell profiling reveals high levels of circulating platelet aggregates in patients with COVID-19. Nat Commun 2021;12:7135. [PMID: 34887400 DOI: 10.1038/s41467-021-27378-2] [Reference Citation Analysis]
26 Lillicrap D, Morrissey JH. Evidence-based medicine in thrombosis and hemostasis: ISTH to the fore. J Thromb Haemost 2021;19:1845-6. [PMID: 34327823 DOI: 10.1111/jth.15436] [Reference Citation Analysis]
27 Abou‐ismail MY, Kapoor S, Citla Sridhar D, Nayak L, Ahuja S. Thrombotic microangiopathies: An illustrated review. Res Pract Thromb Haemost 2022;6. [DOI: 10.1002/rth2.12708] [Reference Citation Analysis]
28 Shaffer J, Grove A. Successful use of a second course of caplacizumab in relapsed thrombotic thrombocytopenic purpura. Platelets 2021;:1-2. [PMID: 34565299 DOI: 10.1080/09537104.2021.1981851] [Reference Citation Analysis]
29 Lemiale V, Valade S, Mariotte E. Unresponsive Thrombotic Thrombocytopenic Purpura (TTP): Challenges and Solutions. Ther Clin Risk Manag 2021;17:577-87. [PMID: 34113115 DOI: 10.2147/TCRM.S205632] [Reference Citation Analysis]
30 Zheng XL. The standard of care for immune thrombotic thrombocytopenic purpura today. J Thromb Haemost 2021;19:1864-71. [PMID: 34060225 DOI: 10.1111/jth.15406] [Reference Citation Analysis]
31 Mingot Castellano ME, Pascual Izquierdo C, González A, Viejo Llorente A, Valcarcel Ferreiras D, Sebastián E, García Candel F, Sarmiento Palao H, Gómez Seguí I, de la Rubia J, Cid J, Martínez Nieto J, Hernández Mateo L, Goterris Viciedo R, Fidalgo T, Salinas R, Del Rio-Garma J; Grupo Español de Aféresis (GEA). Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura. Med Clin (Barc) 2021:S0025-7753(21)00332-8. [PMID: 34266669 DOI: 10.1016/j.medcli.2021.03.040] [Reference Citation Analysis]
32 Sakai K, Fujimura Y, Miyata T, Isonishi A, Kokame K, Matsumoto M. Current prophylactic plasma infusion protocols do not adequately prevent long-term cumulative organ damage in the Japanese congenital thrombotic thrombocytopenic purpura cohort. Br J Haematol 2021;194:444-52. [PMID: 34046888 DOI: 10.1111/bjh.17560] [Reference Citation Analysis]
33 Schwaegermann MK, Hobohm L, Rausch J, Reuter M, Griemert TF, Sivanathan V, Falter T, Sprinzl MF, Lackner KJ, Galle PR, Konstantinides S, Theobald M, von Auer C. COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report. Hamostaseologie 2021. [PMID: 34327693 DOI: 10.1055/a-1497-1054] [Reference Citation Analysis]